Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Rodman & Renshaw Upgrades Encysive Pharmaceuticals

From Standard & Poor's Equity Research

Rodman & Renshaw upgraded Encysive Pharmaceuticals (ENCY) to market outperform.

Analyst Navdeep Jaikaria says an EMEA panel adopts a positive opinion on initial marketing authorization appeals for Thelin. He expects EMEA to approve Thelin for marketing in the European Union within the next 90 days. He says safety issues with Thelin noted by the Food and Drug Administration may not be that serious. He thinks Thelin is more likely to be approved ahead of MYOG's ambrisentan (first half of 2007 vs. second half of 2007.) He also notes that shares have traded down significantly since concerns were cited in the FDA approvable letter earlier this year. Despite today's run-up, he would be a buyer of shares. He has a $10 12-month stock price target.

blog comments powered by Disqus